Floatz logo

PITTSBURGH COMPOUND B UNLABELLED

FTD

Mayo ClinicSmall moleculePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

24 Active assets in the FTD cohort.

Asset / SponsorPhaseRating
FLORTAUCIPIR
Mayo Clinic
Phase 4BBB
FLUDEOXYGLUCOSE
University of Michigan
Phase 4BB
CITALOPRAM
Sunnybrook Health Sciences Centre
Phase 4BB
LEMBOREXANT
Nova Scotia Health Authority
Phase 4BB
IZAFLORTAUCIPIR
University of Pennsylvania
Phase 3BB

View all 41 →

Same molecule, other indications

PITTSBURGH COMPOUND B UNLABELLED is also rated in:

vascular dementiaDormant
BB
Indicative ·
70 / 100
View asset →
vascular dementiaDormant
BB
Indicative ·
65 / 100
View asset →
Alzheimer diseaseDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →